Seroprevalence of hepatitis B virus among adults at high risk for HIV transmission two decades after implementation of nationwide hepatitis B virus vaccination program in Taiwan

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Sun, Hsin Yun ^a   Cheng, Chien Yu ^b   Lee, Nan Yao ^c   Yang, Chia Jui ^d   Liang, Shiou Haur ^e   Tsai, Mao Song ^d   Ko, Wen Chien ^c   Liu, Wen Chun ^a   Wu, Pei Ying ^a   Wu, Cheng Hsin ^a   Lin, Hsi Hsun ^e   Hung, Chien Ching ^a,f,g  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAO YUAN GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e I SHOU UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; LAMIVUDINE; REAGINIC ANTIBODY; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CONTROLLED STUDY; HEPATITIS B; HEPATITIS B VIRUS; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MORBIDITY; MULTIVARIATE ANALYSIS; SEROCONVERSION; SEROPREVALENCE; SEXUAL BEHAVIOR; SYPHILIS; TAIWAN; VACCINATION; VIRUS TRANSMISSION;

ADULT; ANTIBODIES, VIRAL; CHRONIC DISEASE; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MALE; RISK; SEROEPIDEMIOLOGIC STUDIES; SYPHILIS; TAIWAN; VACCINATION;

EID: 84896280193     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090194     Document Type: Article

References (35)

1. Centers for Disease C, Prevention (2006) Hepatitis B vaccination coverage among adults - United States, 2004. MMWR Morbidity and mortality weekly report 55: 509-511.
2. Su WJ, Liu CC, Liu DP, Chen SF, Huang JJ, et al. (2012) Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. The Journal of infectious diseases 205: 757-762.
3. McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, et al. (2011) Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54: 801-807.
4. Chen SM, Kung CM, Yang WJ, Wang HL (2011) Efficacy of the nationwide hepatitis B infant vaccination program in Taiwan. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 52: 11-16.
5. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, et al. (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. The New England journal of medicine 336: 1855-1859.
6. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ (2013) Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA: the journal of the American Medical Association 310: 974-976.
7. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, et al. (2005) Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Annals of internal medicine 142: 333-341. (Pubitemid 40293406)
8. Lu CY, Chiang BL, Chi WK, Chang MH, Ni YH, et al. (2004) Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 40: 1415-1420.
9. Rosenblum L, Darrow W, Witte J, Cohen J, French J, et al. (1992) Sexual practices in the transmission of hepatitis B virus and prevalence of hepatitis delta virus infection in female prostitutes in the United States. JAMA: the journal of the American Medical Association 267: 2477-2481.
10. Osmond DH, Charlebois E, Sheppard HW, Page K, Winkelstein W, et al. (1993) Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. The Journal of infectious diseases 167: 66-71. (Pubitemid 23002838)
11. Piot P, Goilav C, Kegels E (1990) Hepatitis B: transmission by sexual contact and needle sharing. Vaccine 8 Suppl: S37-40; discussion S41-33.
12. Horvath J, Raffanti SP (1994) Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 18: 339-347.
13. Gatanaga H, Yasuoka A, Kikuchi Y, Tachikawa N, Oka S (2000) Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 19: 237-239.
14. Thio CL, Seaberg EC, Skolasky R Jr., Phair J, Visscher B, et al. (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926. (Pubitemid 35472132)
15. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, et al. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control 58: 1-207; quiz CE201-204.
16. Laurence JC (2005) Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. The American journal of medicine 118 Suppl 10A: 75S-83S.
17. Collier AC, Corey L, Murphy VL, Handsfield HH (1988) Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Annals of internal medicine 109: 101-105.
18. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, et al. (2007) Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a largescale survey of free hepatitis screening participants. Journal of the Formosan Medical Association = Taiwan yi zhi 106: 148-155.
19. Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, et al. (1987) A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA: the journal of the American Medical Association 257: 2597-2603.
20. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, et al. (2007) Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 132: 1287-1293.
21. Wu H, Wu PY, Li SY, Chang SY, Liu WC, et al. (2012) Maximising the potential of voluntary counselling and testing for HIV: sexually transmitted infections and HIV epidemiology in a population testing for HIV and its implications for practice. Sexually transmitted infections 88: 612-616.
22. Tseng YT, Sun HY, Chang SY, Wu CH, Liu WC, et al. (2012) Seroprevalence of hepatitis virus infection in men who have sex with men aged 18-40 years in Taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi 111: 431-438.
23. Yang CJ, Lee NY, Lin YH, Lee HC, Ko WC, et al. (2010) Jarisch-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the hiv infection epidemic: incidence and risk factors. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 51: 976-979.
24. Stevens CE, Beasley RP, Tsui J, Lee WC (1975) Vertical transmission of hepatitis B antigen in Taiwan. The New England journal of medicine 292: 771-774.
25. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, et al. (2012) Minimization of hepatitis B infection by a 25-year universal vaccination program. Journal of hepatology 57: 730-735.
26. Chang MH (2007) Hepatitis B virus infection. Seminars in fetal & neonatal medicine 12: 160-167.
27. Sun HY, Chang SY, Yang ZY, Lu CL, Wu H, et al. (2012) Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. Journal of clinical microbiology 50: 781-787.
28. Sun HY, Ko WC, Tsai JJ, Lee HC, Liu CE, et al. (2009) Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination. The American journal of gastroenterology 104: 877-884.
29. Gatanaga H, Hayashida T, Tanuma J, Oka S (2013) Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 56: 1812-1819.
30. Leuridan E, Van Damme P (2011) Hepatitis B and the need for a booster dose. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 53: 68-75.
31. (2000) Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 355: 561-565.
32. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, et al. (2006) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control 55: 1-33; quiz CE31-34.
33. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, et al. (1984) Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. The New England journal of medicine 311: 496-501. (Pubitemid 14059350)
34. Hsu HY, Chang MH, Ni YH, Chen HL (2004) Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 53: 1499-1503.
35. Ponde RA, Cardoso DD, Ferro MO (2010) The underlying mechanisms for the 'anti-HBc alone' serological profile. Archives of virology 155: 149-158.